Emerging Pathways and Promising Agents with Possible Disease Modifying Effect in Osteoarthritis Treatment

被引:29
作者
Jotanovic, Zdravko [1 ]
Mihelic, Radovan [1 ]
Sestan, Branko [1 ]
Dembic, Zlatko [2 ]
机构
[1] Univ Rijeka, Sch Med, Clin Orthopaed Surg Lovran, Lovran, Croatia
[2] Univ Oslo, Dept Oral Biol, Mol Genet Lab, N-0316 Oslo, Norway
关键词
Antibodies; diphosphonates; genetic therapy; interleukins; osteoarthritis; selective estrogen receptor modulators; stem cells; INTERLEUKIN-1; RECEPTOR-ANTAGONIST; CRUCIATE LIGAMENT TRANSECTION; MESENCHYMAL STEM-CELLS; ESTROGEN REPLACEMENT THERAPY; FACTOR-KAPPA-B; RADIOGRAPHIC KNEE OSTEOARTHRITIS; EXPERIMENTAL DOG OSTEOARTHRITIS; REDUCES CARTILAGE DEGENERATION; HUMAN ARTICULAR CHONDROCYTES; BONE REMODELING INHIBITION;
D O I
10.2174/1389450115666140306153115
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Current modalities for osteoarthritis (OA) treatment are partially safe and effective, and only alleviate the disease symptomatology, but do not modify progression and structural changes of the disease. At present, there is no approved safe and effective disease-modifying OA drug (DMOAD) for clinical application. Therefore, there is an urgent need for discovery of DMOAD in order to treat OA. Hopefully, the new DMOADs would also pave the way for better understanding of OA pathophysiology. Given the fact that there is still no adequate remedy that will modify the course of OA, a number of emerging pathways and promising agents with possible DMOAD effect arise targeting cartilage, synovial membrane, and subchondral bone, or using stem cell therapy, and gene therapy. All these methodologies will be described and discussed in this review. Available treatment methodologies for OA are unsatisfactory. In order to properly treat OA in the future, more realistic option will be the use of multiple drugs, instead of single therapy, which is likely to be ineffective in the treatment of such heterogeneous diseases. Which combination of drugs with DMOAD effect will be suitable for the treatment of OA, remains to be determined in future studies.
引用
收藏
页码:635 / 661
页数:27
相关论文
共 257 条
[11]   GENE-TRANSFER TO SYNOVIOCYTES - PROSPECTS FOR GENE TREATMENT OF ARTHRITIS [J].
BANDARA, G ;
ROBBINS, PD ;
GEORGESCU, HI ;
MUELLER, GM ;
GLORIOSO, JC ;
EVANS, CH .
DNA AND CELL BIOLOGY, 1992, 11 (03) :227-231
[12]   INTRAARTICULAR EXPRESSION OF BIOLOGICALLY-ACTIVE INTERLEUKIN-1 RECEPTOR-ANTAGONIST PROTEIN BY EX-VIVO GENE-TRANSFER [J].
BANDARA, G ;
MUELLER, GM ;
GALEALAURI, J ;
TINDAL, MH ;
GEORGESCU, HI ;
SUCHANEK, MK ;
HUNG, GL ;
GLORIOSO, JC ;
ROBBINS, PD ;
EVANS, CH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10764-10768
[13]   Induction of an Antiinflammatory Effect and Prevention of Cartilage Damage in Rat Knee Osteoarthritis by CF101 Treatment [J].
Bar-Yehuda, S. ;
Rath-Wolfson, L. ;
Del Valle, L. ;
Ochaion, A. ;
Cohen, S. ;
Patoka, R. ;
Zozulya, G. ;
Barer, F. ;
Atar, E. ;
Pina-Oviedo, S. ;
Perez-Liz, G. ;
Castel, D. ;
Fishman, P. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (10) :3061-3071
[14]   Mesenchymal stem cells in joint disease and repair [J].
Barry, Frank ;
Murphy, Mary .
NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (10) :584-594
[15]   The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover [J].
Bay-Jensen, Anne-Christine ;
Tabassi, Nadine C. B. ;
Sondergaard, Lene V. ;
Andersen, Thomas L. ;
Dagnaes-Hansen, Frederik ;
Garnero, Patrick ;
Kassem, Moustapha ;
Delaisse, Jean-Marie .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (01) :R9
[16]   Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency [J].
Behets, C ;
Williams, JM ;
Chappard, D ;
Devogelaer, JP ;
Manicourt, DH .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (11) :1821-1826
[17]   Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis [J].
Bellido, M. ;
Lugo, L. ;
Roman-Blas, J. A. ;
Castaneda, S. ;
Calvo, E. ;
Largo, R. ;
Herrero-Beaumont, G. .
OSTEOARTHRITIS AND CARTILAGE, 2011, 19 (10) :1228-1236
[18]   Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis [J].
Bellido, Miriam ;
Lugo, Laura ;
Roman-Blas, Jorge A. ;
Castaneda, Santos ;
Caeiro, Jose R. ;
Dapia, Sonia ;
Calvo, Emilio ;
Largo, Raquel ;
Herrero-Beaumont, Gabriel .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (04)
[19]   The quest for the Holy Grail: a disease-modifying osteoarthritis drug [J].
Berenbaum, Francis .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (06)
[20]   Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee - Results of the two-year multinational knee osteoarthritis structural arthritis study [J].
Bingham, Clifton O., III ;
Buckland-Wright, J. Chris ;
Garnero, Patrick ;
Cohen, Stanley B. ;
DougadoS, Maxime ;
Adarni, Silvano ;
Clauw, Daniel J. ;
Spector, Timothy D. ;
Pelletier, Jean-Pierre ;
Raynauld, Jean-Pierre ;
Strand, Vibeke ;
Simon, Lee S. ;
Meyer, Joan M. ;
Cline, Gary A. ;
Beary, John F. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3494-3507